NCT06974084View on ClinicalTrials.gov

Investigating Measurable PRO Acuity Trial (IMPACT) is a Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Maraviroc and Atorvastatin to Improve Neurocognitive and Physical Function of Subjects With Long COVID-19/Post-Acute Sequelae of COVID-19 (PASC).

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

252

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

February 1, 2026

Study Completion Date

April 30, 2026

Conditions

Long COVID

Interventions

DRUG

Maraviroc (MVC)

Maraviroc, 300mg per tablet. Atorvastatin, 10mg per tablet

DRUG

Atorvastatin, 10mg, 20mg, 40mg

Atorvastatin, 10mg will be given twice daily oral along with Maraviroc, 300-mg

DRUG

Placebo, Maraviroc

Placebo of Maraviroc, 300mg

DRUG

Placebo, Atorvastatin

Placebo of Atorvastin, 10mg

Trial Locations (1)

85719

University of Arizona, Tucson

All Listed Sponsors

lead

HealthBio, Inc.

INDUSTRY

NCT06974084 - Investigating Measurable PRO Acuity Trial (IMPACT) is a Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Maraviroc and Atorvastatin to Improve Neurocognitive and Physical Function of Subjects With Long COVID-19/Post-Acute Sequelae of COVID-19 (PASC). | Biotech Hunter | Biotech Hunter